Status:

COMPLETED

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

21+ years

Phase:

PHASE1

Brief Summary

Safety, tolerability and pharmacokinetics of BIII 890

Eligibility Criteria

Inclusion

  • Participants in the study should be healthy males, range from 21 to 50 years of age and be within +- 20% of their normal weight (Broca-Index) and healthy elderly males and females, \> 60 years of age and be within +-25 % of their normal weight (Broca-Index)
  • In accordance with good clinical practice (GCP) and the local legislation all volunteers will have given their written informed consent prior to admission to the study

Exclusion

  • Volunteers were excluded from the study if the results of the medical examination, laboratory tests or ECG recordings are judged by the investigator to differ significantly from normal clinical values
  • Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Volunteers with diseases of the central nervous system (such as epilepsy), central nervous system (CNS) trauma in their medical history or with psychiatric disorders or neurological disorders
  • Volunteers with known history of relevant orthostatic hypotension, fainting spells or blackouts
  • Volunteers with chronic or relevant acute infections
  • Volunteers with history of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as, judged by the investigator
  • Volunteers who had taken a drug with a long half-life (≥ 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study
  • Volunteers who received any other drugs which could influence the results of the trial during the week prior to the start of the study
  • Volunteers who participated in another study with an investigational drug within the last two months preceding this study
  • Volunteers who smoke (\> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Volunteers who were not able to refrain from smoking on study days
  • Volunteers who drunk more than 60 g of alcohol per day
  • Volunteers who were dependent on drugs
  • Volunteers who participated in excessive physical activities (e.g. competitive sports) during the last week before the study
  • Volunteers who donated blood within the last 4 weeks (≥ 100 mL)

Key Trial Info

Start Date :

January 1 2000

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT02269215

Start Date

January 1 2000

Last Update

October 21 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.